Bridging Interventional Development Gaps (BrIDGs)

Overview

The Bridging Interventional Development Gaps (BrIDGs) program, formerly known as NIH-RAID, assists researchers in advancing promising therapeutic agents through late-stage preclinical development and into clinical testing.

The next receipt date for applications to the BrIDGs program is April 3, 2012. Application information is available here.

The high cost of translating therapeutic discoveries into clinically-available agents can deter the development of promising therapeutics. Researchers may partner with private sector entities to advance projects with significant commercial potential, but high risk ideas or therapies for uncommon disorders frequently do not attract investment. When private sector resources are limited, BrIDGs' in-kind services can help researchers span the gap between the preclinical and clinical stages of therapy development and continue to evaluate agents that may improve the standard of care for patients with a variety of diseases and disorders.

See all related projects for the Bridging Interventional Development Gaps (BrIDGs) Program

Last Updated: February 17, 2012